PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
Abrocitinib (PF-04965842). The study evaluated the safety and efficacy of two doses of abrocitinib, 100 mg and 200 mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. Both doses of abrocitinib met the co-primary study endpoints. Amy Rose 212.733.7410. Source: Pfizer Inc.
40 
Let's personalize your content